These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 19410597)

  • 1. Neuroprotective actions of sex steroids in Parkinson's disease.
    Bourque M; Dluzen DE; Di Paolo T
    Front Neuroendocrinol; 2009 Jul; 30(2):142-57. PubMed ID: 19410597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.
    Bourque M; Dluzen DE; Di Paolo T
    Front Neuroendocrinol; 2012 Apr; 33(2):169-78. PubMed ID: 22387674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
    Morissette M; Al Sweidi S; Callier S; Di Paolo T
    Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens.
    Gillies GE; McArthur S
    Horm Behav; 2010 Jan; 57(1):23-34. PubMed ID: 19538962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease.
    Al Sweidi S; Sánchez MG; Bourque M; Morissette M; Dluzen D; Di Paolo T
    J Neuroendocrinol; 2012 Jan; 24(1):48-61. PubMed ID: 21790809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor mechanisms mediating non-genomic actions of sex steroids.
    Boonyaratanakornkit V; Edwards DP
    Semin Reprod Med; 2007 May; 25(3):139-53. PubMed ID: 17447204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
    D'Astous M; Mendez P; Morissette M; Garcia-Segura LM; Di Paolo T
    Mol Pharmacol; 2006 Apr; 69(4):1492-8. PubMed ID: 16434614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease.
    Gillies GE; Murray HE; Dexter D; McArthur S
    Pharmacol Biochem Behav; 2004 Jul; 78(3):513-22. PubMed ID: 15251260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-genomic sex steroid actions in the vascular system.
    Fu XD; Simoncini T
    Semin Reprod Med; 2007 May; 25(3):178-86. PubMed ID: 17447207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of glutamate in the pathophysiology of Parkinson's disease.
    Blandini F; Greenamyre JT; Nappi G
    Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogen and Parkinson's disease.
    Horstink MW; Strijks E; Dluzen DE
    Adv Neurol; 2003; 91():107-14. PubMed ID: 12442669
    [No Abstract]   [Full Text] [Related]  

  • 13. Integration of steroid hormone initiated membrane action to genomic function in the brain.
    Vasudevan N; Kow LM; Pfaff D
    Steroids; 2005; 70(5-7):388-96. PubMed ID: 15862822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the phosphoinositide-3 kinase and mitogen-activated protein kinase signaling pathways by progesterone and its reduced metabolites in the rat brain.
    Guerra-Araiza C; Amorim MA; Pinto-Almazán R; González-Arenas A; Campos MG; Garcia-Segura LM
    J Neurosci Res; 2009 Feb; 87(2):470-81. PubMed ID: 18752305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
    Liu B; Dluzen DE
    Neuroendocrinology; 2006; 83(5-6):295-302. PubMed ID: 16926530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications for estrogens in Parkinson's disease: an epidemiological approach.
    Ragonese P; D'Amelio M; Savettieri G
    Ann N Y Acad Sci; 2006 Nov; 1089():373-82. PubMed ID: 17261781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estradiol, insulin-like growth factor-I and brain aging.
    Garcia-Segura LM; Diz-Chaves Y; Perez-Martin M; Darnaudéry M
    Psychoneuroendocrinology; 2007 Aug; 32 Suppl 1():S57-61. PubMed ID: 17618061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Male/Female differences in neuroprotection and neuromodulation of brain dopamine.
    Bourque M; Dluzen DE; Di Paolo T
    Front Endocrinol (Lausanne); 2011; 2():35. PubMed ID: 22654803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in Parkinson's disease and other movement disorders.
    Smith KM; Dahodwala N
    Exp Neurol; 2014 Sep; 259():44-56. PubMed ID: 24681088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.